Evidence map›Paper›PMID 30075425›Full record

ArticleJournal of photochemistry and photobiology. B, Biology2018

Comparison of two functionalized fullerenes for antimicrobial photodynamic inactivation: Potentiation by potassium iodide and photochemical mechanisms.

Liyi Huang, Brijesh Bhayana, Weijun Xuan, Richard P Sanchez, Billy J McCulloch, Sanjiv Lalwani, Michael R Hamblin

Abstract readComparative Study
In one paragraph

Article in Journal of photochemistry and photobiology. B, Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Complexation with CNanoscale research letters · 2019
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Liyi HuangDepartment of Infectious Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China; Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Brijesh BhayanaWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Weijun XuanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Department of Otorhinolaryngology, Head and Neck Surgery, First Clinical Medical College and Hospital, Guangxi University of Chinese Medicine, Nanning, China.
Richard P SanchezLynntech Inc, College Station, TX, USA.
Billy J McCullochLynntech Inc, College Station, TX, USA.
Sanjiv LalwaniLynntech Inc, College Station, TX, USA.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. Electronic address: Hamblin@helix.mgh.harvard.edu.
Lynntech (United States) · USGuangxi Medical University · CNGuangxi University of Chinese Medicine · CNHarvard University · USMassachusetts General Hospital · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
Enhanced Efficacy Photodynamic DisinfectionR43AI109938 · NIAID · LYNNTECH, INC. · PI LALWANI, SANJIV · 2014 to 2014
$300k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700NIAID NIH HHS R43 AI109938
6 · The paper itself

Abstract

A new fullerene (BB4-PPBA) functionalized with a tertiary amine and carboxylic acid was prepared and compared with BB4 (cationic quaternary group) for antimicrobial photodynamic inactivation (aPDI). BB4 was highly active against Gram-positive methicillin resistant Staphylococcus aureus (MRSA) and BB4-PPBA was moderately active when activated by blue light. Neither compound showed much activity against Gram-negative Escherichia coli or fungus Candida albicans. Therefore, we examined potentiation by addition of potassium iodide. Both compounds were highly potentiated by KI (1-6 extra logs of killing). BB4-PPBA was potentiated more than BB4 against MRSA and E. coli, while for C. albicans the reverse was the case. Addition of azide potentiated aPDI mediated by BB4 against MRSA, but abolished the potentiation caused by KI with both compounds. The killing ability after light decayed after 24 h in the case of BB4, implying a contribution from hypoiodite as well as free iodine. Tyrosine was readily iodinated with BB4-PPBA plus KI, but less so with BB4. We conclude that the photochemical mechanisms of these two fullerenes are different. BB4-PPBA is more Type 2 (singlet oxygen) while BB4 is more Type 1 (electron transfer). There is also a possibility of direct bacterial killing by electron transfer, but this will require more study to prove.

Indexed as

AminesAnti-Infective AgentsCandida albicansCarboxylic AcidsElectron TransportEscherichia coliFullerenesLightMethicillin-Resistant Staphylococcus aureusPotassium IodideSinglet OxygenAminesAnti-Infective AgentsCarboxylic AcidsFullerenesPotassium IodideSinglet OxygenAntimicrobial photodynamic inactivationFunctionalized fullerenesPhotochemical mechanismPhotoinduced electron transferPotassium iodide potentiationSinglet oxygen

Identifiers

PMID30075425
PMCPMC6118214
OpenAlexW2884402141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.